Dofinansowanie ze środków budżetu państwa
Deklaracja dostępności
The “REGIONAL COVID-HUB” project, carried out by the Institute of Bioorganic Chemistry of the Polish Academy of Sciences with its affiliate, the Poznań Supercomputing and Networking Center, was a response to the challenges posed by the COVID-19 pandemic. Its goal was to apply modern genomic methods in the epidemiology, diagnosis, and prevention of SARS-CoV-2 infections—that is, in the field of so-called genomic epidemiology. The project also included the development of information and communication technologies (ICT) to support the availability and use of public digital e-services related to COVID-19 in Greater Poland.
As part of the project, an online platform (https://wlkp.covidhub.pl/) was developed that enables the visualization and presentation of epidemiological data, as well as the interactive processing and analysis of genomic data. One of the platform’s most important features is an interactive map showing the SARS-CoV-2 genetic variants present and dominant in the in the Greater Poland Voivodeship.
The REGIONAL COVID-HUB platform also supports educational initiatives and raises public awareness about COVID-19 prevention. The platform provides audiovisual and graphic materials, as well as lesson plans, which can be used by lecturers, teachers, college students, and high school students alike. An online communication tool for video conferencing, training, and remote work has also been made available.
In case of the occurrence of new epidemiological threatsin the future, the REGIONAL COVID-HUB platform and the e-services it provides can be used to track the progression of an epidemic or pandemic, identify the main pathways of pathogen transmission, and detect the weakest points in the strategy for protecting citizens from epidemiological threats in the region.
The project received EU funding in the amount of 2,387,587.10 PLN under the Greater Poland Regional Operational Programme for 2014–2020, Measure 2.1 “Development of Electronic Public Services.”
Project implementation period: July 1, 2020–June 30, 2022.
We are pleased to announce that the Institute of Bioorganic Chemistry, Polish Academy of Sciences (IBCH PAS) has secured funding for the project “Preparation of the V-NERVE proposal for the MSCA DN call” under the European Funds for a Smart Economy Programme, specifically the “Grants for Eurogrants” measure. The project is led by Agnieszka Fiszer, PhD, DSc, Assoc. Prof.
Marie Skłodowska-Curie Actions Doctoral Networks (MSCA DN) 2025 is an initiative under the Horizon Europe programme, aimed at improving the quality of doctoral education through international, interdisciplinary and cross-sectoral doctoral programmes. The programme supports the mobility of early-career researchers, the development of research and soft skills, and collaboration between science and industry.
The funded project involved preparing an application for the ‘HORIZON-MSCA-2025-DN-01-01’ call for proposals. As a consortium partner, the IBCH PAS was responsible for co-developing the scientific and training components of the proposal, preparing the description of the host institution and supervisors, the training programme and the budget, as well as for liaising with international partners and verifying the documentation. The Institute also drew up research plans for two PhD students, covering methodology, international collaboration and skills development. Their implementation under the V-NERVE proposal is planned at two departments of the IBCH PAS – the Department of Medical Biotechnology, headed by Agnieszka Fiszer, PhD, DSc, Assoc. Prof., and the Department of Molecular Neurooncology, headed by Katarzyna Rolle, , PhD, DSc, Assoc. Prof.
The aim of the project is to increase the internationalisation and visibility of the IBCH PAS through participation in the MSCA DN 2025 consortium and the submission of a proposal under the Horizon Europe framework programme. The MSCA DN proposal received a very high rating from the experts, confirming its high scientific quality and research potential. Ultimately, it did not receive funding due to the limited budget available under the call.
The total value is 39,601.00 PLN, with co-financing from European Funds amounting to 39,601.00 PLN. Implementation period: 2025–2026.
The project is co-financed by the European Union under the European Funds for a Smart Economy programme.
#FunduszeEuropejskie #FunduszeUE
#EuropeanFunds #EUFunds
Dr. Urszula Kozlowska has become the winner of the 1st nationwide SPARK Poland competition, organized by the Ministry of Science and Higher Education of the Republic of Poland and the Nencki Institute of Experimental Biology of the Polish Academy of Sciences. The SPARK Poland program is an intensive, two-year mentoring initiative developed at Stanford University, aimed at supporting innovative biomedical research, helping to translate research findings into clinical trials, and commercializing novel products, including new therapies. The goal of the SPARK project titled “Development of an affordable therapeutic candidate for Alzheimer's Disease” is to work toward the implementation of a proposed low-cost and safe drug—designed to delay the progression of dementia in Alzheimer's disease—into clinical trials, under the guidance of experienced domestic and international mentors. For this purpose, under the SPARK Poland program, the Ministry of Science and Higher Education of the Republic of Poland will allocate PLN 300,000 to finance R&D and in-kind support, coordinated by the Nencki Institute of Experimental Biology of the Polish Academy of Sciences. Alzheimer's disease is characterized by chronic inflammation, disruption of metabolic processes, and the accumulation of toxic proteins in the cerebral cortex. It is the leading cause of dementia in the elderly. Approximately 50 million people worldwide suffer from Alzheimer's disease, including about 0.5 million in Poland. It is estimated that, due to population aging, this number may triple by 2050. Currently, the only available drugs for Alzheimer’s disease are monoclonal antibodies. The annual cost of such therapy is approximately PLN 100,000, which highlights the urgent need to develop a highly effective and more affordable treatment.
Accessibility Tools
